Related Experiment Video

Updated: Oct 7, 2025

Reverse Yeast Two-hybrid System to Identify Mammalian Nuclear Receptor Residues that Interact with Ligands and/or Antagonists
10:51

Reverse Yeast Two-hybrid System to Identify Mammalian Nuclear Receptor Residues that Interact with Ligands and/or Antagonists

Published on: November 15, 2013

12.9K

Targeting Farnesoid X receptor (FXR) for developing novel therapeutics against cancer

Sosmitha Girisa1, Sahu Henamayee1, Dey Parama1

  • 1Department of Biosciences and Bioengineering, Cancer Biology Laboratory and DBT-AIST International Center for Translational and Environmental Research (DAICENTER), Indian Institute of Technology Guwahati, Guwahati, Assam, 781039, India.

Molecular Biomedicine
|January 10, 2022
PubMed

Insights

Farnesoid X receptor (FXR) plays a key role in cancer development and progression. This review explores FXR's diverse roles in various cancers, highlighting its potential as a diagnostic and therapeutic target.

Area of Science:

  • Molecular Biology
  • Oncology
  • Metabolism

Background:

  • Cancer arises from molecular alterations, including differential expression of Farnesoid X receptor (FXR).
  • FXR, a nuclear receptor, regulates bile, cholesterol, lipid, and glucose metabolism.
  • FXR is implicated in cancer and cardiovascular diseases, major global mortality causes.

Purpose of the Study:

  • To review the diverse roles of Farnesoid X receptor (FXR) in various cancers.
  • To explore FXR's potential as a novel biomarker for cancer diagnosis, prognosis, and therapy.
  • To discuss FXR agonists and antagonists in the context of cancer treatment.

Main Methods:

  • Literature review of recent studies on FXR and cancer.
  • Analysis of FXR's association with cancer development and progression.
  • Examination of FXR's modulation of key cell-signalling pathways and targets.

Main Results:

  • FXR overexpression is linked to cancer development and progression in breast, lung, pancreas, and oesophageal cancers.
  • FXR exhibits tissue-specific and cell-specific roles in different cancer types.
  • FXR modulates critical cancer-related pathways including EGFR/ERK, NF-κB, PI3K/AKT, and Wnt/β-catenin.

Conclusions:

  • FXR is a significant factor in cancer biology, influencing multiple signalling pathways.
  • FXR demonstrates high potential as a novel biomarker for cancer diagnosis, prognosis, and therapy.
  • Targeting FXR with agonists or antagonists may offer new therapeutic strategies for cancer.
Keywords:
AgonistAntagonistCancerCell signallingFXR

More Related Videos

Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment10:33

Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment

Published on: April 25, 2025

520
Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells13:38

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells

Published on: January 18, 2017

12.4K

Related Concept Videos

Transducer Mechanism: Nuclear Receptors01:31

Transducer Mechanism: Nuclear Receptors

Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
1.8K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.9K
Transducer Mechanism: G Protein–Coupled Receptors01:30

Transducer Mechanism: G Protein–Coupled Receptors

G Protein–Coupled Receptors (GPCRs) are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to various stimuli. GPCRs regulate critical physiological pathways and are excellent drug targets for treating diseases such as diabetes, cancer, obesity, depression, or Alzheimer's. Nearly 35% of approved drugs implement their therapeutic effects by selectively interacting with specific GPCRs.
GPCRs are also called heptahelical,...
2.8K
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
7.8K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.0K